Business
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World’s Premier Cancer Research Forum
Cutting-Edge Research Results Showcase AI-Powered Drug DiscoveryVANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced that two of its abstracts have been accepted for presentation at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30 in Ch
About this update from Rakovina Therapeutics Inc
[{"type":"image","alt":"Rakovina Therapeutics Inc","displaySize":"","headline":null,"caption":"Rakovina Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8pDE_lHFFxIFLy74uLNlBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b","width":300,"height":101}},"lazy":false},{"type":"text","content":"Cutting-Edge Research Results Showcase AI-Powered Drug Discovery","length":64,"tagName":"p"},{"type":"text","content":"VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced that two of its abstracts have been accepted for presentation at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30 in Chicago, Illinois.","length":452,"tagName":"p"},{"type":"text","content":"The AACR Annual Meeting is widely considered the most prestigious global forum for cancer research. It is where the world’s leading scientists, clinicians, and biotech innovators gather to unveil next-generation oncology breakthroughs. Rakovina’s acceptance to present, highlights growing recognition for its pioneering work at the intersection of AI technology and precision cancer therapy.","length":391,"tagName":"p"},{"type":"text","content":"AI-Designed Therapies Poised to Transform Cancer Treatment","length":58,"tagName":"p"},{"type":"text","content":"Rakovina will present two abstracts at the meeting, the first: Discovery of novel PARP1-selective inhibitors for treatment of brain tumors using artificial intelligence, explores the use of artificial intelligence (AI) to develop a novel, brain-penetrant, PARP1-selective inhibitor for treating brain tumors. Current PARP inhibitors face challenges such as poor blood-brain barrier (BBB) permeability and off-target effects due to PARP2 inhibition. By leveraging Deep Docking, a deep learning-based virtual screening method, alongside generative AI algorithms, researchers rapidly identified potential compounds with strong PARP1 selectivity...